

# Is exclusion of tenofovir from antiretroviral regimens safe in Africa: insights on hepatitis B from the switch to DTG/3TC (Sungura) study


**Loice Achieng Ombajo<sup>1,2</sup>, Jeremy Penner<sup>2,3</sup>, Joseph Nkuranga<sup>1,2</sup>, Victor Omodi<sup>1,2</sup>, Edwin Otieno<sup>1,2</sup>, Michelle Kisare<sup>4</sup>, Simon Wahome<sup>5</sup>, Florentius Ndinya<sup>6</sup>, Carolyne Wafula<sup>6</sup> For the Sungura study group**

1. Department of Clinical Medicine and Therapeutics, University of Nairobi, Nairobi, Kenya; 2. Center for Epidemiological Modelling and Analysis, University of Nairobi, Nairobi, Kenya; 3. Department of Family Practice, University of British Columbia, Vancouver, Canada; 4. ViiV HealthCare, London, UK; 5. Kenyatta National Hospital, Nairobi, Kenya; 6. Jaramogi Oginga Odinga Teaching and Referral Hospital, Kisumu, Kenya

## BACKGROUND


- Tenofovir, the WHO recommended nucleoside reverse transcriptase inhibitor in antiretroviral therapy, is useful for treatment of both HIV and HBV
- However, as comorbidities such as kidney and bone disease rise, particularly in older populations, dual drug therapies that exclude tenofovir are increasingly attractive
- It is unclear how best to deploy these regimens in contexts with high HBV prevalence and low uptake of HBV vaccination
- Reactivation of HBV remains a potential risk in those with previous exposure in whom tenofovir is withdrawn

### HIV/HBV Coinfection



## METHODS


- The Sungura study (NCT06444620) is a phase 3 single arm clinical trial at multiple sites in Kenya enrolling participants
  - aged  $\geq 60$  years
  - VL  $< 50$  copies/mL
  - on bicitgravir/emtricitabine/tenofovir alafenamide (B/F/TAF)



- Participants with evidence of HBV infection during the screening visit were excluded; this was defined as:
  - Having a positive HBV surface antigen (HBsAg)
  - Having a negative HBV surface antigen (HBsAg) and:
    - a positive HBV core antibody (anti-HBc) and a negative HBV surface antibody (anti-HBs)
    - a positive HBV core antibody (anti-HBc) and HBV surface antibody (anti-HBs) of  $< 10$  IU
- All participants were switched to DTG/3TC at enrollment
- Liver chemistries were done at baseline and at week 24
- We evaluate the incidence of elevation of liver transaminases at 24 weeks post withdrawal of TAF
- The study is continuing to week 96

## RESULTS

- Between July and September 2024, 227 participants on B/F/TAF were screened for enrolment into the study
- As shown in figure 3, 29 of the 30 participants who were excluded from the study lacked evidence of immunity to HBV:
  - 1 HBsAg positive
  - 28 with anti-HBs of  $< 10$  IU (18 with anti-HBs of  $< 5$  IU and 10 anti-HBs of between 5 and  $< 10$  IU)



- The median age was 66 years (range 62-81) and 49.2% were female.
- At week 24, no ALT or AST elevations were observed and there were no incident HBV infections
- Additionally, high rates of HIV-1 suppression were observed

## CONCLUSION

- Prior hepatitis B exposure is common in older PWH, majority of whom have immunity and can be safely transitioned to a two-drug regimen that excludes tenofovir
- However, HBV serology panels to identify people at risk of HBV reactivation are not routinely available across much of sub-Saharan Africa, and further work is needed to evaluate the necessity of such screening

## ACKNOWLEDGEMENT

This is an investigator-initiated trial funded by ViiV Healthcare and sponsored by the University of Nairobi. We would like to thank the study participants, study sites and personnel at Jaramogi Oginga Odinga Teaching and Referral Hospital and the Kenyatta National Hospital, and the Ministry of Health through the National AIDS and STI Control Program

## CONTACT

[loisea@uonbi.ac.ke](mailto:loisea@uonbi.ac.ke)